GLIP-20
Description
- Contains Teneligliptin 20 mg – a DPP-4 inhibitor
- Improves glycemic control by increasing insulin and reducing glucagon
- Effective in both fasting and post-meal blood sugar control
- Can be used alone or in combination with other antidiabetics
- Low risk of hypoglycemia and weight neutrality
- Supports HbA1c reduction in type 2 diabetes patients
- Convenient once-daily oral dosing
Composition
Teneligliptin 20 mg
Benefits
GLIP-20 helps achieve better glycemic control without causing significant weight gain or hypoglycemia, making it a safe and convenient choice for long-term diabetes management. It is well-tolerated and can be used alone or with other medications like Metformin, Sulfonylureas, or Insulin. The once-daily dosing and good safety profile support improved patient compliance. GLIP-20 also contributes to lowering HbA1c levels, thus helping to reduce the risk of long-term diabetes-related complications.
Introduction
GLIP-20 is an oral antidiabetic tablet containing Teneligliptin 20 mg, a potent and long-acting DPP-4 (Dipeptidyl Peptidase-4) inhibitor. It is used in the management of type 2 diabetes mellitus to improve glycemic control, either as monotherapy or in combination with other antidiabetic agents. Teneligliptin enhances the body’s natural ability to regulate blood sugar by increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner, offering effective control of postprandial and fasting blood glucose levels.
